Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
- Conditions
- C85.1B-cell lymphoma, unspecified
- Registration Number
- DRKS00011932
- Lead Sponsor
- niversitätsklinikum FreiburgMedizinische Klinik IHämatologie, Onkologie und Stammzelltransplantation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 53
Key inclusion criteria:
1. Immunocompetent patients with newly-diagnosed primary central nervous system B-cell lymphoma.
2. Age > 65 years plus patients between 65-70 years, who are not eligible for treatment within the MATRix/IELSG43 trial.
3. Histologically or cytologically assessed diagnosis of B-cell lymphoma by local pathologist.
4. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy.
5. Disease exclusively located in the CNS.
6. At least one measurable lesion.
7. ECOG-Performance Status = 2.
8. Patients eligible for intensive treatment according to physician´s choice.
9. Written informed consent obtained according to international guidelines and local laws by patient or authorized legal representative in case patient is temporarily legally not competent due to his or her disease.
Key exclusion criteria:
1. Congenital or acquired immunodeficiency.
2. Systemic lymphoma manifestation (outside the CNS).
3. Isolated ocular lymphoma without manifestation in the brain parenchyma or spinal cord.
4. Previous or concurrent malignancies with the exception of surgically cured carcinoma in-situ of the cervix, carcinoma of the skin or other kinds of cancer without evidence of disease for at least 5 years.
5. Previous systemic Non-Hodgkin lymphoma at any time.
6. Inadequate renal function (creatinine clearance <60 ml/min).
7. Inadequate hepatic, cardiac or pulmonary function according to physician`s decision.
8. Active hepatitis B or C disease.
9. HIV infection, previous organ transplantation or other clinical evident form of immunodeficiency.
10. Concurrent treatment with other experimental drugs or participation in a clinical trial within the last thirty days before the start of this study.
11. Third space fluid accumulation >500 ml.
12. Hypersensitivity to study treatment or any component of the formulation.
13. Taking any medications likely to cause interactions with the study medication.
14. Known or persistent abuse of medication, drugs or alcohol.
15. Patient without legal capacity and who is unable to understand the nature, significance and consequences of the study and without designated legal representative.
16. Persons who are in a relationship of dependency/employment to the sponsor and/ or investigator.
17. Any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint: progression free survival (PFS) at 1 year: time from start of treatment until disease progression or death from any cause, whichever occurs first.
- Secondary Outcome Measures
Name Time Method •Rate of complete responses (CR) on day +30 after HDT-ASCT<br>•Progression-free survival (PFS) as time from start of treatment until progression, relapse or death from any cause, whatever happens first<br>•Overall survival (OS) as time from start of treatment until death from any cause<br>•Rate of neurotoxicity on day + 30 after HDT-ASCT and continuously thereafter<br>•Non relapse mortality (NRM)<br>•(Serious) adverse events ([S]AEs): from the first administration of the study medication until day 30 after HDT-ASCT<br>